Robert Bissonnette News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Robert bissonnette. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Robert Bissonnette Today - Breaking & Trending Today

Ruxolitinib Consistent in Safety, Tolerability Over 52-Weeks in Children with Extensive Atopic Dermatitis

Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.
....

United States , Robert Bissonnette , Innovaderm Research , Innovaderm Research Robert Bissonnette , Revolutionizing Atopic Dermatitis , Maximum Use Trial , Global Assessment , Treatment Success , Dermatology Life Quality Index , Patient Oriented Eczema Measure , Infant Dermatitis Quality ,

JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis

Researchers found that the percentage of patients with a PASI 75 response was higher among those receiving JNJ-77242113 vs placebo. ....

Robert Bissonnette , Janssen Research , Innovaderm Research , Healthday News , New England Journal , Psoriasis Area , Severity Index ,

Robert Bissonnette, MD: Safety Profile, Future Research on New Oral IL-23 Inhibitor for Psoriasis

During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics. ....

Robert Bissonnette , Innovaderm Research , Chief Executive Officer , Il 23 , Jnj 2113 ,

Robert Bissonnette, MD: Discussing the First Oral IL-23 Inhibitor for Psoriasis

In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis. ....

Robert Bissonnette , Innovaderm Research , Chief Executive Officer , Jnj 2113 , Il 23 ,

JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis

Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide. ....

Robert Bissonnette , Janssen Research , Innovaderm Research , Healthday News , New England Journal , Psoriasis Area , Severity Index ,